Non-cancerous Pain, Opioid Use
Conditions
Brief summary
Many treatments with WHO grade III opioids are being introduced in the rheumatology department for non-cancerous pain. The duration of this treatment prescribed at discharge is often uncontrolled and sometimes leads to significant addiction. The team at the local pain center recommends an average duration of 28 days for this type of pain. There is a full-time pharmacy intern in the rheumatology department. The aim of this work is to evaluate the impact of a targeted pharmaceutical interview on the duration of the morphine treatment initiated during hospitalization.
Interventions
BEHAVIORALAdmission conciliation interview
Previous treatment conciliation at hospital admission
BEHAVIORALDischarge conciliation interview
Allocated treatment during hospital stay
BEHAVIORALTargeted pharmaceutical interview
Specific information about treatment delivered by pharmacist
Sponsors
University Hospital, Rouen
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
SUPPORTIVE_CARE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 75 Years
Healthy volunteers
No
Inclusion criteria
* Age ≥ 18 and \< 75 years old when entering the rheumatology department * Hospitalization in the rheumatology department * Patient with acute non-traumatic musculoskeletal disease * Patient not taking grade III opioid treatment * Patient affiliated to a social security scheme * Patient having read and understood the information letter and signed the consent form * Patient present on a day which the pharmacy intern is present
Exclusion criteria
* Presence of cancer, fibromyalgia, already diagnosed at inclusion * Patient does not understand French * Patient with Current or past opioid addiction * Person deprived of liberty by administrative or judicial decision
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Total duration of opioid treatment | 6 months |
Secondary
| Measure | Time frame |
|---|---|
| Rate of patients exceeding 28 days of cumulative duration of treatment | 6 months |
| Rate of patients exceeding 90 days of cumulative duration of treatment | 6 months |
Countries
France
Contacts
PRINCIPAL_INVESTIGATOROlivier VITTECOQ, Pr
University Hospital, Rouen
PRINCIPAL_INVESTIGATORRemi VARIN, Pr
University Hospital, Rouen
PRINCIPAL_INVESTIGATORCatherine CHENAILLER, Dr
University Hospital, Rouen
Outcome results
None listed